Total Payments
$219,172
2024 Payments
$17,305
Companies
12
Transactions
32
Medicare Patients
465
Medicare Billing
$64,421
Payment Breakdown by Category
Education$200,059 (91.3%)
Consulting$11,860 (5.4%)
Travel$5,337 (2.4%)
Food & Beverage$1,915 (0.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $200,059 | 5 | 91.3% |
| Consulting Fee | $11,860 | 4 | 5.4% |
| Travel and Lodging | $5,337 | 4 | 2.4% |
| Food and Beverage | $1,915 | 19 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $201,116 | 12 | $0 (2022) |
| BeiGene USA, Inc. | $7,667 | 5 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $4,924 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,499 | 4 | $0 (2024) |
| Eisai Inc. | $2,398 | 2 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $125.00 | 1 | $0 (2018) |
| PFIZER INC. | $110.70 | 1 | $0 (2017) |
| Incyte Corporation | $110.36 | 1 | $0 (2021) |
| Lilly USA, LLC | $106.53 | 1 | $0 (2017) |
| AbbVie, Inc. | $88.06 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,305 | 9 | BeiGene USA, Inc. ($7,667) |
| 2023 | $59.43 | 3 | Merck Sharp & Dohme LLC ($59.43) |
| 2022 | $97.71 | 1 | Ipsen Biopharmaceuticals, Inc ($97.71) |
| 2021 | $100,110 | 2 | Ipsen Biopharmaceuticals, Inc ($100,000) |
| 2020 | $100,150 | 2 | Ipsen Biopharmaceuticals, Inc ($100,150) |
| 2019 | $281.36 | 3 | Ipsen Biopharmaceuticals, Inc ($281.36) |
| 2018 | $253.54 | 2 | Ipsen Biopharmaceuticals, Inc ($128.54) |
| 2017 | $914.53 | 10 | Ipsen Biopharmaceuticals, Inc ($458.46) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 06/26/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,370.00 | General |
| Category: Oncology | ||||||
| 06/26/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $28.26 | General |
| Category: Oncology | ||||||
| 05/30/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Travel and Lodging | In-kind items and services | $4,500.00 | General |
| Category: Oncology | ||||||
| 05/30/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Oncology | ||||||
| 05/30/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Travel and Lodging | In-kind items and services | $530.19 | General |
| Category: Oncology | ||||||
| 05/30/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Travel and Lodging | Cash or cash equivalent | $279.01 | General |
| Category: Oncology | ||||||
| 05/30/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $107.33 | General |
| Category: Oncology | ||||||
| 05/20/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| 12/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2022 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $97.71 | General |
| Category: Oncology/Endocrinology | ||||||
| 07/16/2021 | Incyte Corporation | PEMAZYRE (Drug) | Food and Beverage | Cash or cash equivalent | $110.36 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 02/10/2021 | Ipsen Biopharmaceuticals, Inc | — | Education | Cash or cash equivalent | $100,000.00 | General |
| 03/07/2020 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug) | Education | Cash or cash equivalent | $100,000.00 | General |
| Category: Oncology/Endocrinology | ||||||
| 01/23/2020 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology/Endocrinology | ||||||
| 10/03/2019 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug) | Food and Beverage | In-kind items and services | $68.68 | General |
| Category: Oncology/Endocrinology | ||||||
| 04/30/2019 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $97.87 | General |
| Category: Oncology/Endocrinology | ||||||
| 01/17/2019 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $114.81 | General |
| Category: Oncology/Endocrinology | ||||||
| 06/04/2018 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $128.54 | General |
| 01/10/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 12/14/2017 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $106.32 | General |
| Category: Oncology | ||||||
| 12/01/2017 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $12.42 | General |
| 11/17/2017 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $120.56 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 67 | 141 | $50,177 | $13,394 |
| 2022 | 3 | 101 | 195 | $56,795 | $16,252 |
| 2021 | 4 | 188 | 305 | $79,973 | $23,277 |
| 2020 | 3 | 109 | 176 | $45,496 | $11,498 |
Total Patients
465
Total Services
817
Medicare Billing
$64,421
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 39 | 85 | $34,595 | $9,221 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 28 | 56 | $15,582 | $4,173 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 55 | 130 | $34,645 | $9,920 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 32 | 50 | $19,417 | $5,544 | 28.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 15 | $2,733 | $787.72 | 28.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 68 | 157 | $28,165 | $8,329 | 29.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 56 | 82 | $20,764 | $6,284 | 30.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 40 | 40 | $21,444 | $5,665 | 26.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 24 | 26 | $9,600 | $2,999 | 31.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 62 | 124 | $29,920 | $7,634 | 25.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 20 | 20 | $10,136 | $2,646 | 26.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 27 | 32 | $5,440 | $1,218 | 22.4% |
About Sarbajit Mukherjee
Sarbajit Mukherjee is a Medical Oncology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2012. The National Provider Identifier (NPI) number assigned to this provider is 1003164427.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sarbajit Mukherjee has received a total of $219,172 in payments from pharmaceutical and medical device companies, with $17,305 received in 2024. These payments were reported across 32 transactions from 12 companies. The most common payment nature is "Education" ($200,059).
As a Medicare-enrolled provider, Mukherjee has provided services to 465 Medicare beneficiaries, totaling 817 services with total Medicare billing of $64,421. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Miami, FL
- Active Since 08/15/2012
- Last Updated 03/27/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1003164427
Products in Payments
- SOMATULINE DEPOT (Drug) $100,529
- TEVIMBRA (Drug) $7,667
- Lenvima (Drug) $2,398
- Somatuline Depot (Drug) $127.73
- CALQUENCE (Drug) $125.00
- EMPLICITI (Biological) $124.19
- ELIQUIS (Drug) $110.70
- PEMAZYRE (Drug) $110.36
- CYRAMZA (Drug) $106.53
- Onivyde (Drug) $106.32
- KEYTRUDA (Biological) $59.43
- JEVTANA (Drug) $14.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Miami
Dr. Neil Love, M.d, M.D
Medical Oncology — Payments: $5.6M
Medical Oncology $5.6M
Jonathan Trent, M.d., Ph. D, M.D., PH. D
Medical Oncology — Payments: $397,021
Medical Oncology $397,021
Craig Moskowitz, Md, MD
Medical Oncology — Payments: $190,115
Medical Oncology $190,115
Orlando Silva, Md, MD
Medical Oncology — Payments: $87,713
Medical Oncology $87,713
Gilberto Lopes, Md, MD
Medical Oncology — Payments: $71,778
Medical Oncology $71,778
Dr. Guenther Koehne, M.d, M.D
Medical Oncology — Payments: $45,409
Medical Oncology $45,409